Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 2/20 | 0.52 |
| ▸ | AKT1 | P31749 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1979460 | 0.80 | ROCK2 (0.43) | AKT2AKT1MAPTLMNAALDH1A1 | |
| SCHEMBL1015607 | 0.80 | IDO1 (0.61) | AKT2AKT1MAPTLMNAALDH1A1 | |
| SCHEMBL16432987 | 0.79 | AKT2 (0.76) | AKT2AKT1ROCK2ACVR1 | |
| SCHEMBL15689115 | 0.79 | AKT2 (0.76) | AKT2AKT1ROCK2ACVR1 | |
| SCHEMBL1978170 | 0.79 | ROCK2 (0.47) | AKT2AKT1MAPTLMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL1013817 | 0.78 | IDO1 (0.60) | AKT2AKT1MAPTLMNAALDH1A1 | |
| SCHEMBL29071558 | 0.77 | AKT2 (0.43) | AKT2AKT1MAPTLMNARAB9A | |
| SCHEMBL5070333 | 0.77 | MAPT (0.56) | MAPTLMNAALDH1A1KDM4EGAA | |
| SCHEMBL6423919 | 0.77 | CA1 (0.67) | MAPTLMNAALDH1A1KDM4EGAA | |
| SCHEMBL28198 | 0.77 | CA1 (0.67) | MAPTLMNAALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4206197-B1 | PREPARATION METHOD FOR NOVEL RHO-RELATED PROTEIN KINASE INHIBITOR AND INTERMEDIATE IN PREPARATION METHOD | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-20230303534-A1 | PREPARATION METHOD FOR NOVEL RHO-RELATED PROTEIN KINASE INHIBITOR AND INTERMEDIATE IN PREPARATION METHOD | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303534-A1 | PREPARATION METHOD FOR NOVEL RHO-RELATED PROTEIN KINASE INHIBITOR AND INTERMEDIATE IN PREPARATION METHOD | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303534-A1 | PREPARATION METHOD FOR NOVEL RHO-RELATED PROTEIN KINASE INHIBITOR AND INTERMEDIATE IN PREPARATION METHOD | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| EP-4206197-A1 | PREPARATION METHOD FOR NOVEL RHO-RELATED PROTEIN KINASE INHIBITOR AND INTERMEDIATE IN PREPARATION METHOD | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2023-07-05 | — | — | EP | disclosed |
| CN-115996727-A | Process for preparing Rho related protein kinase inhibitors and intermediates in the process | 北京泰德制药股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-111601807-B | Exo-azaspiro inhibitors of MENIN-MLL interactions | 詹森药业有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20230039917-A1 | EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-09 | — | — | US | disclosed |
| US-11396517-B1 | Exo-aza spiro inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-26 | — | — | US | disclosed |
| WO-2022042711-A1 | PREPARATION METHOD FOR NOVEL RHO-RELATED PROTEIN KINASE INHIBITOR AND INTERMEDIATE IN PREPARATION METHOD | 北京泰德制药股份有限公司 | 2022-03-03 | — | — | WO | disclosed |
| EP-3313825-A1 | GLUCOSE UPTAKE INHIBITORS | Kadmon Corporation, LLC (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2017024996-A1 | HYDROXY AMIDINE DERIVATIVE, PREPARATION METHOD AND USE IN MEDICINE THEREOF | 江苏恒瑞医药股份有限公司 | 2017-02-16 | — | — | WO | disclosed |
| WO-2016210330-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC (US) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016210331-A1 | TREATMENT OF INFECTIOUS DISEASES WITH GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC (US) | 2016-12-29 | — | — | WO | disclosed |
| WO-2014079850-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-30 | — | — | WO | disclosed |
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2010-05-06 | — | — | US | disclosed |
| CN-101679440-A | Pyrrolopyrimidine derivatives as jak3 inhibitors | PALAU PHARMA SA | 2010-03-24 | — | — | CN | disclosed |
| EP-2142550-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | Palau Pharma, S.A. (ES) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119792-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S. A. (ES) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | AKT2 1555/4885AKT1 1203/4885MAPT 4202/4885 |
| US-20230303534-A1 | PREPARATION METHOD FOR NOVEL RHO-RELATED PROTEIN KINASE INHIBITOR AND INTERMEDIATE IN PREPARATION METHOD | ROCK1, ROCK2, ARHGDIA | AKT2 134/4885AKT1 61/4885MAPT 1991/4885 |
| US-11396517-B1 | Exo-aza spiro inhibitors of menin-MLL interaction | BMI1, MLLT1, EED | AKT2 1137/4885AKT1 396/4885MAPT 3725/4885 |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | AKT2 1555/4885AKT1 1203/4885MAPT 4202/4885 |
| US-20230039917-A1 | EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION | BMI1, MLLT1, SUZ12 | AKT2 1320/4885AKT1 554/4885MAPT 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.